{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:42:57Z","timestamp":1792111377625,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Psychiatry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/s2215-0366(26)00276-2","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:49:43Z","timestamp":1792018183000},"page":"931-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data"],"prefix":"10.1016","volume":"13","author":[{"given":"Najmeh","family":"Davoodian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana J","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urska","family":"Arnautovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McLure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Panizzutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Rossell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Taquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Upthegrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Walder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Mohebbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2215-0366(26)00276-2_bib1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","article-title":"Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses","volume":"2","author":"Henderson","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib3","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/S2215-0366(26)00276-2_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator-blinded, randomised controlled trial in Australia","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tem.2022.06.005","article-title":"GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?","volume":"33","author":"Horska","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/S2215-0366(26)00276-2_bib6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S2215-0366(26)00276-2_bib7","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 receptor agonists","volume":"394","author":"Rosen","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/S2215-0366(26)00276-2_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543784.2021.1951702","article-title":"Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential","volume":"30","author":"Flintoff","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/S2215-0366(26)00276-2_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/YIC.0000000000000595","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks","volume":"41","author":"Carminati","year":"2026","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/S2215-0366(26)00276-2_bib10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","article-title":"Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: a systematic review and meta-analysis","volume":"82","author":"Ebrahimi","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/cells14050387","article-title":"Insights into the roles of GLP-1, DPP-4, and SGLT2 at the crossroads of cardiovascular, renal, and metabolic pathophysiology","volume":"14","author":"Gaggini","year":"2025","journal-title":"Cells"},{"key":"10.1016\/S2215-0366(26)00276-2_bib14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records","volume":"11","author":"Xie","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2215-0366(26)00276-2_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057227","article-title":"NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data","volume":"12","author":"Patel","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/S2215-0366(26)00276-2_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3390\/brainsci15050499","article-title":"Is there a link between type 2 diabetes mellitus and negative symptoms in schizophrenia? A scoping review","volume":"15","author":"Bitter","year":"2025","journal-title":"Brain Sci"},{"key":"10.1016\/S2215-0366(26)00276-2_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00125-025-06555-8","article-title":"Regression from prediabetes to normoglycaemia and the role of cardiometabolic risk factors on the subsequent risk of developing type 2 diabetes","volume":"69","author":"Davoodian","year":"2026","journal-title":"Diabetologia"},{"key":"10.1016\/S2215-0366(26)00276-2_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat Ment Health"},{"key":"10.1016\/S2215-0366(26)00276-2_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079475","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/S2215-0366(26)00276-2_bib20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamapsychiatry.2024.2412","article-title":"Semaglutide in psychiatry\u2014opportunities and challenges","volume":"81","author":"Agarwal","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00712","article-title":"From metabolism to mind: the expanding role of the GLP-1 receptor in neurotherapeutics","volume":"22","author":"Roy","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/S2215-0366(26)00276-2_bib22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neubiorev.2021.01.005","volume":"125","author":"Fern\u00e1ndez-Abascal","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/S2215-0366(26)00276-2_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamapsychiatry.2025.4308","article-title":"Prospects of GLP-1 therapies for addiction and mental health comorbidities-quo vadis?: A review","volume":"83","author":"Farokhnia","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1594334","article-title":"Sex differences in schizophrenia: symptomatology, treatment efficacy and adverse effects","volume":"16","author":"Moniem","year":"2025","journal-title":"Front Psychiatry"},{"key":"10.1016\/S2215-0366(26)00276-2_bib26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S2215-0366(15)00003-6","article-title":"New perspectives on schizophrenia in later life: implications for treatment, policy, and research","volume":"2","author":"Cohen","year":"2015","journal-title":"Lancet Psychiatry"}],"container-title":["The Lancet Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036626002762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036626002762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:45:01Z","timestamp":1792093501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215036626002762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2215036626002762"],"URL":"https:\/\/doi.org\/10.1016\/s2215-0366(26)00276-2","relation":{},"ISSN":["2215-0366"],"issn-type":[{"value":"2215-0366","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data","name":"articletitle","label":"Article Title"},{"value":"The Lancet Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2215-0366(26)00276-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}